As of November 14, 2026, Mersana Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 6, 2026 (Form 8-K, January 6, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Mersana Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Mersana Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-06. Every row below is cited to the filing it comes from, and this page adds each new change as Mersana Therapeutics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2025-05-06 (layoff filings and notices).
Also on the record for Mersana Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by 683 Capital Management, LLC | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by 683 Capital Management, LLC | 7.03% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Schonfeld Strategic Advisors LLC | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.2% of the class | 5%+ stakes | Source |
| January 9, 2026 | Stake report, Schedule 13G/A, by Nextech Crossover I GP S.a. r.l. | — | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13D/A, by Bain Capital Life Sciences Fund II, L.P. | — | 5%+ stakes | Source |
| January 6, 2026 | Acquired by Day One Biopharmaceuticals, Inc. | — | Acquisition | Source |
| November 24, 2025 | Stake report, Schedule 13G, by 683 Capital Management, LLC | 5.47% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Schonfeld Strategic Advisors LLC | 5.48% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13D/A, by Bain Capital Life Sciences Fund II, L.P. | 4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Schonfeld Strategic Advisors LLC | 4.55% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Mersana Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Mersana Therapeutics, Inc. and the records around it.
Mersana Therapeutics, Inc. elsewhere on the record
- Acquisition Jan 2026
Companies that share a holder
- Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: Xilio Therapeutics, Inc. (May 2026), C4 Therapeutics, Inc. (Oct 2025)
- Nextech Crossover I GP S.a. r.l. also filed stake reports on 2 other companies: Tango Therapeutics, Inc. (Aug 2026), ORIC Pharmaceuticals, Inc. (Aug 2025)
- Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Inhibrx Biosciences, Inc. (Nov 2026), Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026)
Watch Mersana Therapeutics, Inc.
Get an email when Mersana Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mersana Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mersana Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mersana Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-06 | Reported | not named in the filing | 8-K, 2026-01-06 |
New leaders reset buying decisions — get the Full Report on Mersana Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Mersana Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Mersana Therapeutics, Inc.Every change, in the filing's words
Reported
In accordance with the terms of the Merger Agreement, (i) each of Lawrence M. Alleva, William H. Dere, Allene M. Diaz, Andrew A. F. Hack, Kristen M. Hege, Martin Huber, David Mott and Anna Protopapas resigned from his or her respective position as a member of the Company's board of directors and all committees thereof, effective as of the Effective Time and (ii) Charles N. York II and Adam Dubow, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time.
- These resignations were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies or practices.
- In accordance with the terms of the Merger Agreement, each officer of Purchaser immediately prior to the Effective Time became an officer of the Company effective as of the Effective Time.
- The officers of Purchaser immediately prior to the Effective Time were Charles N. York II as Chief Executive Officer, President, Chief Financial Officer, Chief Operating Officer and Treasurer and Adam Dubow as Chief Compliance Officer, General Counsel and Secretary.
- Effective immediately following completion of the Merger, all of the incumbent officers of the Company, as of immediately prior to the Effective Time, ceased being officers of the Company.
Tools for this story
Each opens in a new tab, filled in for Mersana Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
